Steve Sabus

Steve Sabus currently serves as a Commercial Strategy Advisor at Remedy Plan Therapeutics and an Advisor at Third Opinion, roles held since June 2024. Previously, Steve held the position of Chief Commercial Officer at Syndax Pharmaceuticals from December 2022 to April 2024, and at Turning Point Therapeutics for a brief period before its acquisition by Bristol-Myers Squibb in August 2022. Steve's extensive experience at Astellas Pharma includes serving as Senior Vice President and Head of the Oncology and Medical Specialties Business Units from April 2020 to June 2022, General Manager for Astellas Pharma Canada from February 2018 to April 2020, and various vice president roles from October 2010 to February 2018. Steve began a career at Johnson & Johnson, where tenure lasted from 2000 to 2007 as Region Business Director.